Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27810440 | 1.00 | MAPK1 (0.41) | MAPK1DHODHPPARDALDH1A1THRA | |
| Hydrochloric Acid SCHEMBL1295995 | 0.99 | MAPK1 (0.40) | MAPK1DHODHPPARDALDH1A1THRA | |
| Hydrochloric Acid SCHEMBL1295997 | 0.99 | MAPK1 (0.40) | MAPK1DHODHPPARDALDH1A1THRA | |
| SCHEMBL27810438 | 0.85 | THRB (0.38) | MAPK1PPARDALDH1A1THRATHRB | |
| SCHEMBL12103645 | 0.85 | THRB (0.38) | MAPK1PPARDALDH1A1THRATHRB | |
| SCHEMBL12106827 | 0.84 | MAPK1 (0.40) | MAPK1PPARDTHRATHRB | |
| SCHEMBL27830881 | 0.84 | ITGB3 (0.35) | MAPK1DHODHPPARDTHRATHRB | |
| SCHEMBL12160383 | 0.84 | ACACB (0.35) | THRATHRB | |
| Hydrochloric Acid SCHEMBL1295968 | 0.84 | THRB (0.38) | MAPK1DHODHPPARDALDH1A1THRA | |
| Hydrochloric Acid SCHEMBL1295966 | 0.84 | THRB (0.38) | MAPK1DHODHPPARDALDH1A1THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| EP-2383270-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-11-02 | — | — | EP | disclosed |
| CN-102083813-A | Piperidinyl gpcr agonists | PROSIDION LTD | 2011-06-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | MAPK1 793/4885DHODH 3868/4885PPARD 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.